Comprehensive, easy-to-understand information about this condition
How we create this content →Report Generation Failed
We couldn't automatically generate the report. This may be due to temporary service issues.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning developmental delay, behavioral abnormalities, and neuropsychiatric disorders
Updated Feb 4, 2026
New selective morpholine trace amine-associated receptor 1 partial agonists demonstrate promising preclinical effects for neuropsychiatric disorders and show good tolerance in healthy volunteers. These findings could pave the way for future therapeutic options in this area.